Ideaya Biosciences (IDYA) Stock News

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 95,600 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.

The stock options were granted at an exercise price of $22.29 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in two major healthcare investor conferences in June 2025. CEO Yujiro S. Hata will participate in fireside chats at the 2025 Jefferies Global Healthcare Conference on June 4th at 8:10 AM ET, hosted by Dr. Maury Raycroft, and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9th at 10:40 AM ET, hosted by Corinne Johnson. Live audio webcasts will be available on IDEAYA's investor relations website, with replays accessible for 30 days after the events.

IDEAYA Biosciences (NASDAQ: IDYA) has granted non-qualified stock options to nine newly hired employees as part of their employment inducement package. The Compensation Committee approved options to purchase 664,600 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan. The options were priced at $20.05 per share, matching IDEAYA's closing price on the Nasdaq Global Select Market on the grant date. These 10-year options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.

IDEAYA Biosciences (NASDAQ: IDYA) reported Q1 2025 financial results with $1.05 billion in cash reserves, extending runway into 2029. Key highlights include: Over 300 patients enrolled in darovasertib and crizotinib registrational trial for metastatic uveal melanoma (MUM), with median PFS results targeted by YE 2025. The company received FDA Breakthrough Therapy Designation for darovasertib in neoadjuvant UM treatment. Q1 2025 showed a net loss of $72.2 million, with R&D expenses at $70.9 million and G&A expenses at $13.5 million. IDEAYA's pipeline progress includes IDE849 Phase 1 initiation in the U.S., IDE275 presentation at AACR 2025, and plans for three additional IND filings in 2025 (PRMT5, B7H3/PTK7 ADC, and KAT6/7). The company strengthened its leadership team with new CFO Joshua Bleharski and SVP of Technical Operations Shanthakumar Tyavanagimatt.

IDEAYA Biosciences (NASDAQ: IDYA) has received FDA IND clearance for IDE849, a potential first-in-class DLL3 TOP1 ADC, to begin Phase 1 clinical trials in solid tumors. The drug targets DLL3, which is upregulated in multiple cancer types including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), and non-small cell lung cancer (NSCLC). In ongoing Phase 1 trials by partner Hengrui Pharma, IDE849 has shown multiple partial responses with predominantly Grade 1 or 2 treatment-related adverse events. Clinical data from over 40 SCLC patients will be presented in Q3 2025. IDEAYA plans to evaluate IDE849 as both a monotherapy and in combination with their PARG inhibitor IDE161 in the second half of 2025, with the U.S. trial starting at a dose equivalent to current expansion doses showing confirmed partial responses.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in two major investor relations events in May 2025:

• Barclays Hosted Event on May 8th, 2025 at 11:00 AM ET - featuring a fireside chat with President and CEO Yujiro S. Hata, hosted by Peter Lawson, Managing Director and Equity Research Analyst
• 2025 RBC Capital Markets Global Healthcare Conference on May 20th, 2025 at 8:30 AM ET - including a fireside chat with CEO Hata, hosted by Gregory Renza, Director and Senior Biotechnology Research Analyst

Live audio webcasts will be available on the IDEAYA website's Investors/Events section, with recordings accessible for 30 days after each event.

IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of non-qualified stock options to four newly hired employees through its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved options to purchase 185,400 shares of common stock at an exercise price of $19.07 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.

The stock options, granted under Nasdaq Listing Rule 5635(c)(4), feature a 10-year term with a four-year vesting schedule: 25% vesting after the first year, followed by monthly installments over three years. These inducement grants are specifically designed for new employees who were not previously with IDEAYA, contingent upon their continued service with the company.

IDEAYA Biosciences (NASDAQ:IDYA) has announced a successful FDA Type D meeting regarding the Phase 3 registrational trial design for darovasertib as neoadjuvant therapy for primary uveal melanoma (UM). The company plans to initiate the Phase 3 randomized trial in H1 2025, involving approximately 520 patients randomized 2:1 to treatment versus control.

The trial will include two cohorts: 120 enucleation-eligible UM patients and 400 plaque brachytherapy (PB) eligible patients. For the enucleation cohort, the primary endpoint is eye preservation rate, while the PB cohort's primary endpoint focuses on vision loss measurement. Both cohorts require no detriment to Event-Free-Survival as a secondary endpoint.

Darovasertib, a protein kinase C inhibitor, has received FDA Breakthrough Therapy Designation for neoadjuvant therapy in enucleation-recommended primary UM and Fast Track designation for combination therapy in metastatic UM. The trial will use 300mg BID darovasertib as the move-forward dose.

IDEAYA Biosciences (IDYA) has initiated a Phase 1/2 expansion study evaluating the combination of IDE397, its MAT2A inhibitor, with Trodelvy® in MTAP-deletion urothelial cancer (UC). The expansion is based on preliminary safety and clinical efficacy data.

IDE397 is a potent and selective small molecule inhibitor targeting MAT2A in solid tumors with MTAP-deletion, which affects approximately 26% of UC patients. The combination represents a potential first-in-class treatment approach for MTAP-deletion UC, addressing an unmet medical need with no currently approved targeted therapies.

A clinical program update on the IDE397-Trodelvy combination is expected in 2025. Additionally, IDEAYA plans to initiate a combination trial of IDE397 with IDE892, their MTA-cooperative PRMT5 inhibitor, in the second half of 2025.